3,473 results match your criteria European journal of heart failure[Journal]


February 2019 at a glance: pathophysiology, exercise capacity, diuretics and valve disease.

Authors:
Marco Metra

Eur J Heart Fail 2019 Feb;21(2):135-136

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1256DOI Listing
February 2019

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.

Eur J Heart Fail 2019 Feb 11. Epub 2019 Feb 11.

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard University, Boston, MA, USA.

Aims: To assess differences in diuretic dose requirements in patients treated with sacubitril/valsartan compared with enalapril in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial.

Methods And Results: Overall, 8399 patients with New York Heart Association class II-IV heart failure and reduced LVEF were randomized to sacubitril/valsartan 200 mg bid or enalapril 10 mg twice daily. Loop diuretic doses were assessed at baseline, 6, 12, and 24 months, and furosemide dose equivalents were calculated via multiplication factors (2x for torsemide and 40x for bumetanide). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1402DOI Listing
February 2019

Unravelling the effect of sacubitril/valsartan on loop diuretic dosing.

Eur J Heart Fail 2019 Feb 11. Epub 2019 Feb 11.

University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1410DOI Listing
February 2019

Left atrial dysfunction: the next key target in heart failure with preserved ejection fraction.

Eur J Heart Fail 2019 Feb 8. Epub 2019 Feb 8.

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1420DOI Listing
February 2019

Clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy.

Eur J Heart Fail 2019 Feb 8. Epub 2019 Feb 8.

Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Aims: We investigated the clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy (PiCM).

Methods And Results: From a retrospective analysis of 1418 consecutive pacemaker patients, 618 were found to have a preserved baseline left ventricular ejection fraction (LVEF), follow-up echocardiographic data, and no history of heart failure (HF). PiCM was defined as a reduction in LVEF (< 50%) along with either (i) a ≥ 10% decrease in LVEF, or (ii) new-onset regional wall motion abnormality unrelated to coronary artery disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1427DOI Listing
February 2019
1 Read

Applying data science approaches to identify frequent flyers in heart failure: rise of the machines.

Eur J Heart Fail 2019 Feb 7. Epub 2019 Feb 7.

Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1387DOI Listing
February 2019

The Janus-faced Fontan circulation: unravelling its elusive pathophysiology.

Eur J Heart Fail 2019 Feb 7. Epub 2019 Feb 7.

Center for Congenital Heart Diseases, Department of Cardiology, University Medical Center Groningen, University of of Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1415DOI Listing
February 2019

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.

Eur J Heart Fail 2019 Feb 4. Epub 2019 Feb 4.

Department of Cardiology, CARIM School for Cardiovascular Diseases Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.

Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ejhf.1406
Publisher Site
http://dx.doi.org/10.1002/ejhf.1406DOI Listing
February 2019
2 Reads
6.526 Impact Factor

Long-term prognosis in patients with Takotsubo syndrome.

Eur J Heart Fail 2019 Feb 4. Epub 2019 Feb 4.

Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1417DOI Listing
February 2019

Long-term outcome in patients with Takotsubo syndrome presenting with severely reduced left ventricular ejection fraction.

Eur J Heart Fail 2019 Feb 4. Epub 2019 Feb 4.

Department of Cardiology, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy.

Aim: To evaluate the long-term outcome of patients with Takotsubo syndrome (TTS) and severely reduced left ventricular ejection fraction (LVEF ≤ 35%) at presentation.

Methods And Results: The study population included 326 patients (mean age 69.5 ± 10. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ejhf.1373
Publisher Site
http://dx.doi.org/10.1002/ejhf.1373DOI Listing
February 2019
1 Read

Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.

Eur J Heart Fail 2019 Feb 4. Epub 2019 Feb 4.

Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Aims: Plasma volume expansion is clinically and prognostically relevant in individuals with heart failure. Prior cohorts either excluded or had limited representation of patients with heart failure with preserved ejection fraction (HFpEF). We aimed to examine the relationship between calculated plasma volume status (PVS) and outcomes in HFpEF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1407DOI Listing
February 2019

The vicious cycle of arrhythmia and myocardial fibrosis.

Eur J Heart Fail 2019 Jan 30. Epub 2019 Jan 30.

Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1421DOI Listing
January 2019
1 Read

Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction.

Eur J Heart Fail 2019 Jan 30. Epub 2019 Jan 30.

Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.

Aims: To assess the association between atrial fibrillation (AF) and mortality, and also the association between resting heart rate (HR) and mortality in both sinus rhythm (SR) and AF in patients with heart failure with preserved ejection fraction (HFpEF).

Methods And Results: A total of 9090 patients with HFpEF (ejection fraction ≥ 50%) were included from the Swedish Heart Failure registry; 4296 (47%) had SR and 4794 (53%) had AF. Patients with AF were older (80. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1389DOI Listing
January 2019

Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy.

Eur J Heart Fail 2019 Jan 30. Epub 2019 Jan 30.

Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.

Aims: The landmark STICH trial found that surgical revascularization compared to medical therapy alone improved survival in patients with heart failure (HF) of ischaemic aetiology and an ejection fraction (EF) ≤ 35%. However, the interaction between the burden of medical co-morbidities and the benefit from surgical revascularization has not been previously described in patients with ischaemic cardiomyopathy.

Methods And Results: The STICH trial (ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1404DOI Listing
January 2019
6.526 Impact Factor

Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?

Eur J Heart Fail 2019 Jan 30. Epub 2019 Jan 30.

University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1425DOI Listing
January 2019

Lung ultrasound for the diagnosis of acute heart failure: time to upgrade current indication?

Eur J Heart Fail 2019 Jan 28. Epub 2019 Jan 28.

Heart Failure Unit, Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1414DOI Listing
January 2019

Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial.

Eur J Heart Fail 2019 Jan 28. Epub 2019 Jan 28.

Division of Emergency Medicine and High Dependency Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy.

Aims: Although acute decompensated heart failure (ADHF) is a common cause of dyspnoea, its diagnosis still represents a challenge. Lung ultrasound (LUS) is an emerging point-of-care diagnostic tool, but its diagnostic performance for ADHF has not been evaluated in randomized studies. We evaluated, in patients with acute dyspnoea, accuracy and clinical usefulness of combining LUS with clinical assessment compared to the use of chest radiography (CXR) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in conjunction with clinical evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1379DOI Listing
January 2019
1 Read

The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial.

Eur J Heart Fail 2019 Jan 28. Epub 2019 Jan 28.

Department of Medicine, University of Mississippi, Jackson, MS, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1416DOI Listing
January 2019

Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor.

Eur J Heart Fail 2019 Jan 24. Epub 2019 Jan 24.

Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg, Saarland University, Germany.

Aims: Atrial fibrillation is the most prevalent sustained arrhythmia associated with arrhythmic ventricular contractions, incident heart failure, increased morbidity and mortality. The relationship between arrhythmic contractions and ventricular remodelling is incompletely understood. The aim of this study was to characterize the influence of irregular contractions on pro-fibrotic signalling in neonatal rat ventricular cardiomyocytes (NRVM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1392DOI Listing
January 2019
1 Read

Haemodynamic profiles in adult Fontan patients: associated haemodynamics and prognosis.

Eur J Heart Fail 2019 Jan 23. Epub 2019 Jan 23.

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.

Aims: The Fontan operation is associated with significant long-term morbidity and mortality, posing challenges in management. No haemodynamic classification has been established to aid management and prognostication of patients with Fontan palliation. Our aim was to assess haemodynamic profiles for Fontan patients and evaluate their relationships to prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1365DOI Listing
January 2019

'Finding the biomarker' for transcatheter mitral valve repair.

Authors:
Gian Paolo Ussia

Eur J Heart Fail 2019 Feb 23;21(2):193-195. Epub 2019 Jan 23.

Facoltà Dipartimentale di Medicina e Chirurgia, University Campus Bio-Medico, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1344DOI Listing
February 2019

Potential role for interleukin-1 in the cardio-renal syndrome.

Eur J Heart Fail 2019 Jan 22. Epub 2019 Jan 22.

Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1403DOI Listing
January 2019
6.526 Impact Factor

Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure.

Eur J Heart Fail 2019 Jan 22. Epub 2019 Jan 22.

Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow, UK.

Aims: Even if treatment controls symptoms, patients with heart failure may still be congested. We aimed at assessing the prevalence and clinical relevance of congestion in outpatients with chronic heart failure.

Methods And Results: We recorded clinical and ultrasound [lung B-lines; inferior vena cava (IVC) diameter; internal jugular vein diameter before and after a Valsalva manoeuvre (JVD ratio)] features of congestion in heart failure patients during a routine check-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1383DOI Listing
January 2019
1 Read

Sex hormones in heart failure revisited?

Eur J Heart Fail 2019 Jan 22. Epub 2019 Jan 22.

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1408DOI Listing
January 2019
1 Read

Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort.

Eur J Heart Fail 2019 Jan 18. Epub 2019 Jan 18.

University of Melbourne, Parkville, Australia.

Aims: We investigated which serum amino-terminal pro-B-type-natriuretic peptide (NT-proBNP) levels inform heart failure (HF) risk in a community-based population at increased cardiovascular disease (CVD) risk.

Methods And Results: Inclusion criteria were age ≥ 60 years with one or more of self-reported hypertension, diabetes, heart disease, abnormal heart rhythm, cerebrovascular disease, or renal impairment. Exclusion criteria were known HF, ejection fraction (EF) < 50%, or more than mild valve abnormality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1381DOI Listing
January 2019
1 Read

Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction.

Eur J Heart Fail 2019 Jan 16. Epub 2019 Jan 16.

Department of Cardiology and Pneumology and The German Center for Cardiovascular Research (DZHK), University Medicine Göttingen (UMG), Göttingen, Germany.

Aims: Cardiac contractility modulation (CCM) improves symptoms and exercise tolerance and reduces heart failure (HF) hospitalizations over 6-month follow-up in patients with New York Heart Association (NYHA) class III or IV symptoms, QRS < 130 ms and 25% ≤ left ventricular ejection fraction (LVEF) ≤ 45% (FIX-HF-5C study). The current prospective registry study (CCM-REG) aimed to assess the longer-term impact of CCM on hospitalizations and mortality in real-world experience in this same population.

Methods And Results: A total of 140 patients with 25% ≤ LVEF ≤ 45% receiving CCM therapy (CCM-REG ) for clinical indications were included. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ejhf.1374
Publisher Site
http://dx.doi.org/10.1002/ejhf.1374DOI Listing
January 2019
3 Reads

Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction.

Eur J Heart Fail 2019 Jan 16. Epub 2019 Jan 16.

Baker Heart and Diabetes Institute, Melbourne, Australia.

Background: Elevated left atrial (LA) pressure, particularly during exercise, is associated with symptomatic status and survival in patients with heart failure with preserved ejection fraction (HFpEF). We aimed to characterize the contribution of abnormal LA mechanical properties to exercise haemodynamics in HFpEF.

Methods And Results: Simultaneous echocardiography and right heart catheterization were performed in 71 subjects with left ventricular ejection fraction ≥ 50% referred for assessment of exertional dyspnoea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1399DOI Listing
January 2019
1 Read

January 2019 at a glance: prognostic assessment, left ventricular assist devices, disease management and quality of care.

Authors:
Marco Metra

Eur J Heart Fail 2019 Jan;21(1):1-2

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1254DOI Listing
January 2019

Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years.

Eur J Heart Fail 2019 Feb 11;21(2):208-217. Epub 2019 Jan 11.

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Aims: Exercise-derived parameters, specifically peak exercise oxygen uptake (peak VO ) and minute ventilation/carbon dioxide relationship slope (VE/VCO slope), have a pivotal prognostic value in heart failure (HF). It is unknown how the prognostic threshold of peak VO and VE/VCO slope has changed over the last 20 years in parallel with HF prognosis improvement.

Methods And Results: Data from 6083 HF patients (81% male, age 61 ± 13 years), enrolled in the MECKI score database between 1993 and 2015, were retrospectively analysed. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ejhf.1364
Publisher Site
http://dx.doi.org/10.1002/ejhf.1364DOI Listing
February 2019
6 Reads

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Eur J Heart Fail 2019 Jan 11. Epub 2019 Jan 11.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University Hospital, Bologna, Italy.

Aims: Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH) after defect correction have a poor prognosis compared with other CHD-PAH patients. Therefore, it is important that these patients are treated as early and effectively as possible. Evidence supporting the use of PAH therapies in patients with corrected CHD-PAH from randomised controlled trials is limited. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ejhf.1375
Publisher Site
http://dx.doi.org/10.1002/ejhf.1375DOI Listing
January 2019
10 Reads

Trimethylamine N-oxide and risk of heart failure progression: marker or mediator of disease.

Eur J Heart Fail 2019 Jan 9. Epub 2019 Jan 9.

Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1409DOI Listing
January 2019

Transcatheter edge-to-edge mitral valve repair: what is the measure of success?

Eur J Heart Fail 2019 Feb 9;21(2):205-207. Epub 2019 Jan 9.

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ejhf.1405
Publisher Site
http://dx.doi.org/10.1002/ejhf.1405DOI Listing
February 2019
2 Reads

Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records.

Eur J Heart Fail 2019 Jan 7. Epub 2019 Jan 7.

Farr Institute of Health Informatics Research, Institute of Health Informatics, University College London, London, UK.

Aims: Several risk factors for incident heart failure (HF) have been previously identified, however large electronic health records (EHR) datasets may provide the opportunity to examine the consistency of risk factors across different subgroups from the general population.

Methods And Results: We used linked EHR data from 2000 to 2010 as part of the UK-based CALIBER resource to select a cohort of 871 687 individuals 55 years or older and free of HF at baseline. The primary endpoint was the first record of HF from primary or secondary care. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ejhf.1350
Publisher Site
http://dx.doi.org/10.1002/ejhf.1350DOI Listing
January 2019
4 Reads

Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.

Eur J Heart Fail 2019 Jan 2. Epub 2019 Jan 2.

Comprehensive Heart Failure Center, University Hospital, Würzburg, Germany.

Aim: Serelaxin is a recombinant human relaxin-2 hormone, which confers receptor-mediated vasodilatation in a tissue-specific fashion. The RELAX-AHF-EU study assessed the effect of serelaxin when added to standard-of-care (SoC) therapy on worsening heart failure (WHF)/all-cause death through Day 5 in patients hospitalised for acute heart failure (AHF) in Europe.

Methods And Results: This multicentre, prospective, randomised, open-label, blinded-endpoint validation study enrolled hospitalised AHF patients and randomised (2:1) eligible patients (mild-to-moderate renal impairment and systolic blood pressure ≥ 125 mmHg) within 16 h of presentation with signs/symptoms of AHF, to receive 48 h intravenous infusion of 30 μg/kg/day serelaxin + SoC or SoC alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1368DOI Listing
January 2019

The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail 2019 Feb 1;21(2):137-155. Epub 2019 Jan 1.

IRCCS, San Raffaele Pisana, Rome, Italy.

The vast majority of acute heart failure episodes are characterized by increasing symptoms and signs of congestion with volume overload. The goal of therapy in those patients is the relief of congestion through achieving a state of euvolaemia, mainly through the use of diuretic therapy. The appropriate use of diuretics however remains challenging, especially when worsening renal function, diuretic resistance and electrolyte disturbances occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1369DOI Listing
February 2019
1 Read

Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.

Eur J Heart Fail 2019 Feb 1;21(2):218-226. Epub 2019 Jan 1.

INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France.

Background: The 6-minute walk test (6MWT) is a simple and inexpensive way of measuring exercise capacity in patients with heart failure (HF) that predicts morbidity and mortality. However, there are few reports from large multicentre cohorts assessing the predictive value of baseline and changing walk distance.

Methods And Results: In BIOSTAT-CHF, a 6MWT was performed at baseline (n = 1714) and 9 months (n = 1520). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ejhf.1380
Publisher Site
http://dx.doi.org/10.1002/ejhf.1380DOI Listing
February 2019
4 Reads
6.526 Impact Factor

E-health in self-care of heart failure patients: promises become reality.

Eur J Heart Fail 2019 Feb 28;21(2):247-248. Epub 2018 Dec 28.

Heart Failure Unit, Cardiology, Guglielmo da Saliceto Hospital, Piacenza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1386DOI Listing
February 2019

Cardiac resynchronization therapy improves survival in selected patients with moderately impaired ejection fraction - the importance of left ventricular remodelling.

Eur J Heart Fail 2018 Dec 28. Epub 2018 Dec 28.

Division of Cardiology, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1401DOI Listing
December 2018

Adrenomedullin in heart failure: pathophysiology and therapeutic application.

Eur J Heart Fail 2019 Feb 28;21(2):163-171. Epub 2018 Dec 28.

Division of Cardiology, Stony Brook University, Stony Brook, NY, USA.

Adrenomedullin (ADM) is a peptide hormone first discovered in 1993 in pheochromocytoma. It is synthesized by endothelial and vascular smooth muscle cells and diffuses freely between blood and interstitium. Excretion of ADM is stimulated by volume overload to maintain endothelial barrier function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1366DOI Listing
February 2019
1 Read

Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibility-related adverse events.

Eur J Heart Fail 2018 Dec 28. Epub 2018 Dec 28.

Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.

Aims: Left ventricular assist device (LVAD) therapy improves the haemodynamics of advanced heart failure patients. However, it is unknown whether haemodynamic optimization improves haemocompatibility-related adverse events (HRAEs). This study aimed to assess HRAEs in patients with optimized haemodynamics. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ejhf.1372
Publisher Site
http://dx.doi.org/10.1002/ejhf.1372DOI Listing
December 2018
1 Read

The Heart Failure Virtual Consultation - a powerful tool for the delivery of specialist care and the democratization of knowledge in the community.

Eur J Heart Fail 2019 Feb 28;21(2):255-256. Epub 2018 Dec 28.

Heart Failure Unit, St. Vincent's University Hospital, School of Medicine, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1390DOI Listing
February 2019

Cardiac rehabilitation in heart failure after the ExTraMATCH II study: who still believes?

Eur J Heart Fail 2019 Feb 28;21(2):257. Epub 2018 Dec 28.

Department of Cardiac Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Care and Research Institutes of Pavia, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1388DOI Listing
February 2019

Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure.

Eur J Heart Fail 2019 Feb 28;21(2):235-237. Epub 2018 Dec 28.

Brigham and Women's Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1382DOI Listing
February 2019

Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction.

Eur J Heart Fail 2018 Dec 28. Epub 2018 Dec 28.

University of Rochester Medical Center, Rochester, NY, USA.

Aims: Despite our prior report suggesting heart failure (HF) risk reduction from cardiac resynchronization therapy with defibrillator (CRT-D) in mild HF patients with higher left ventricular ejection fraction (LVEF > 30%), data on mortality benefit in this cohort are lacking. We aimed to assess long-term mortality benefit from CRT-D in mild HF patients by LVEF > 30%.

Methods And Results: Among 1274 patients with mild HF and left bundle branch block enrolled in MADIT-CRT, we analysed long-term effects of CRT-D vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1357DOI Listing
December 2018
1 Read

The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer.

Eur J Heart Fail 2018 Dec 27. Epub 2018 Dec 27.

CESP, Université Paris-Saclay, Villejuif, France.

Background: Paediatric cancer survivors have a high risk of developing cardiac diseases, and the most frequent cardiac disease is heart failure (HF). The radiation dose-volume effects in the heart and cardiac substructures have not been explored in childhood cancer survivors (CCS). Therefore, the role of irradiated heart volume in the occurrence of HF among this population remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1376DOI Listing
December 2018
6.526 Impact Factor

The new Heart Failure Association journal - ESC Heart Failure.

Eur J Heart Fail 2018 Dec;20(12):1657-1663

Division of Cardiology and Metabolism, Department of Cardiology (CVK), Charité, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1362DOI Listing
December 2018

December 2018 at a glance: new imaging methods, translational cardiology and non-medical treatment.

Authors:
Marco Metra

Eur J Heart Fail 2018 Dec;20(12):1613-1614

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1016DOI Listing
December 2018